CLINICAL TRIALS PROFILE FOR PREDNISOLONE SODIUM PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for prednisolone sodium phosphate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01039103 ↗ | Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) | Terminated | Galapagos NV | Phase 2 | 2009-12-01 | Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol. Main objective is to assess the occurrence of new gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment. |
| NCT01505088 ↗ | Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis | Completed | Eyegate Pharmaceuticals, Inc. | Phase 3 | 2011-12-01 | The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis. |
| NCT01534195 ↗ | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model | Completed | ORA, Inc. | Phase 4 | 2012-01-01 | The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: - Ocular itching - Conjunctival redness |
| NCT01601106 ↗ | Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease | Unknown status | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1/Phase 2 | 2011-09-01 | Cardiovascular disease(CVD) is the leading cause of morbidity and mortality in developed nations. CVD is primarily caused by atherosclerosis, a systemic disease characterized by lipid deposition in the subendothelial space with a concomitant, low-grade inflammatory reaction.(Fuster, Moreno et al. 2005) To date, most therapeutic interventions aimed at lowering CVD have thus far focused on modulating lipid levels, either lowering LDLc or increasing HDLc levels. Yet, since the introduction of statins 20 years ago, there have been few breakthroughs in the treatment of this disease. A promising strategy to reduce CVD is to directly target inflammation at the level of the vessel wall.(van Leuven, van Wijk et al.; Libby 2002) A potential drawback of anti-inflammatory strategies pertains to the thin line between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression. Therefore, continuous low dosed anti-inflammatory drugs have great potential as novel treatment strategies. In the present project, the investigators propose to inject liposomal glucocorticoids intravenously in patients with an increased risk of atherosclerotic disease aiming to reduce vessel wall inflammation. |
| NCT01647685 ↗ | A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort | Unknown status | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1/Phase 2 | 2012-05-01 | A promising strategy to reduce CVD is to directly target inflammation at the level of the vessel wall. A potential drawback of anti-inflammatory strategies pertains to the thin line between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression. One of the strategies to limit systemic immunosuppression is to strive for local delivery and prolonged efficacy and low systemic burden of the drug by encapsulating the compound in liposomes. Liposome-encapsulated drugs efficiently target lesions and accumulate at a much higher extent at desired areas of interest. Thus, local delivery and prolonged efficacy can be very important tools to overcome the potential drawback anti-inflammatory drugs; namely an inappropriate immune suppression. In the present project, the investigators therefore aim to evaluate the delivery and superior efficacy of Nanocort above Prednison or placebo in patients with peripheral artery disease due to atherosclerosis. Because these patients will undergo an endarteriectomy the investigators will be able to collect atherosclerotic material after drug administration and thus evaluate the local delivery and compare the effects of Nanocort to Prednison or Placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for prednisolone sodium phosphate
Condition Name
Clinical Trial Locations for prednisolone sodium phosphate
Trials by Country
Clinical Trial Progress for prednisolone sodium phosphate
Clinical Trial Phase
Clinical Trial Sponsors for prednisolone sodium phosphate
Sponsor Name
